Back

Comparison of AAV9-driven motor neuron transduction following different CNS-directed delivery methods in mice

Mole, A. J.; Sander, C. F.; Parmar, A. R.; Williams, A. J.; Azzouz, M.; Hautbergue, G. M.; Shaw, P. J.; Ferraiuolo, L.; Mead, R. J.

2025-07-03 neuroscience
10.1101/2025.07.01.662642 bioRxiv
Show abstract

AbstractO_ST_ABSBackgroundC_ST_ABSGene therapies are promising for diseases previously considered incurable. Adeno-associated virus serotype 9 (AAV9) demonstrates remarkable tropism for motor neurons (MNs) and represents an exciting candidate to target genetic causes of motor neuron diseases like amyotrophic lateral sclerosis (ALS). However, systemic delivery risks immunogenicity and off-target effects, therefore localised delivery to the CNS is advantageous. New methodWe assessed MN transduction in wild-type mice using AAV9-controlled, cytomegalovirus-promoter driven, enhanced GFP expression. Intra-cisterna magna (ICM) and intra-cerebroventricular (ICV) methods were compared. Four weeks post-delivery, GFP positivity in MN and astrocytes were quantified via immunohistochemical approaches and viral genome copy number determined by qPCR. ResultsAll delivery methods achieved high MN transduction in lumbar spinal cord (>68%). Unilateral ICV delivery provided the highest and most consistent levels (89 {+/-} 3%), and minimal peripheral viral copies. ICV delivery resulted in higher astrocytic transduction, most notably in the cortex. Brainstem MN transduction was high with all methods (>55%). We failed to find evidence of neuronal transduction in motor cortex. Viral genome copies trended higher in spinal cord and brainstem with ICV approaches, however further work is required to understand how bilateral delivery leads to such profound increases. Comparison to existing methodsWhilst several routes of administration into cerebrospinal fluid exist, direct comparisons for targeting MNs in vivo remain limited. ConclusionsOverall, consideration of gene therapy delivery methods is critical to ensure that the most appropriate administration route is chosen to reach MNs effectively, selectively, and at high levels to exact biological effects. HighlightsO_LICSF delivery of AAV9 targets >68% of lumbar spinal cord (SC) motor neurons C_LIO_LIUnilateral ICV yields high and consistent lumbar SC motor neuron transduction (>88%) C_LIO_LIUnilateral ICV results in the lowest number of peripheral viral copies C_LIO_LIICV targets significantly more astrocytes, particularly in cortex C_LIO_LIBilateral ICV leads to significantly higher viral copies in the liver C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC="FIGDIR/small/662642v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@bd83a5org.highwire.dtl.DTLVardef@df63aorg.highwire.dtl.DTLVardef@a09142org.highwire.dtl.DTLVardef@1a0887a_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
13.1%
2
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.1%
6.5%
3
PLOS ONE
4510 papers in training set
Top 30%
5.0%
4
Journal of Translational Medicine
46 papers in training set
Top 0.1%
5.0%
5
Journal of Controlled Release
39 papers in training set
Top 0.2%
4.3%
6
Bioengineering & Translational Medicine
21 papers in training set
Top 0.1%
3.7%
7
Pharmaceutics
21 papers in training set
Top 0.1%
3.7%
8
Scientific Reports
3102 papers in training set
Top 42%
3.0%
9
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 0.8%
2.4%
10
Journal of Neuroscience Methods
106 papers in training set
Top 0.6%
2.1%
11
Nature Communications
4913 papers in training set
Top 46%
2.1%
50% of probability mass above
12
Frontiers in Neuroanatomy
14 papers in training set
Top 0.1%
1.8%
13
Molecular Therapy
71 papers in training set
Top 1%
1.8%
14
Imaging Neuroscience
242 papers in training set
Top 2%
1.8%
15
eneuro
389 papers in training set
Top 5%
1.7%
16
Wellcome Open Research
57 papers in training set
Top 1.0%
1.5%
17
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.1%
1.3%
18
Cell Reports Methods
141 papers in training set
Top 3%
1.3%
19
Journal of Neural Engineering
197 papers in training set
Top 1%
1.3%
20
Cell Reports Medicine
140 papers in training set
Top 5%
1.3%
21
Frontiers in Molecular Neuroscience
43 papers in training set
Top 0.5%
1.0%
22
iScience
1063 papers in training set
Top 24%
1.0%
23
PLOS Neglected Tropical Diseases
378 papers in training set
Top 4%
1.0%
24
Brain Stimulation
112 papers in training set
Top 1%
1.0%
25
PeerJ
261 papers in training set
Top 13%
0.8%
26
Neurotherapeutics
11 papers in training set
Top 0.4%
0.8%
27
Archives of Clinical and Biomedical Research
28 papers in training set
Top 2%
0.8%
28
Stem Cell Reports
118 papers in training set
Top 0.9%
0.8%
29
Molecular Pharmaceutics
16 papers in training set
Top 0.5%
0.8%
30
Viruses
318 papers in training set
Top 5%
0.8%